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Background/Aims: The Response Evaluation Criteria in 
Solid Tumors (RECIST) 1.1 and modified RECIST (mRECIST) 
criteria have been used to assess treatment responses for 
hepatocellular carcinoma (HCC) patients. We investigated 
which criteria provides better survival predictions in HCC 
patients treated with transarterial radioembolization (TARE). 
Methods: In total, 102 patients with unresectable intrahe-
patic HCC, who were treated with TARE between 2012 and 
2017, were reviewed retrospectively. The treatment response 
after TARE was evaluated at 1, 3, and 6 months by the mRE-
CIST and RECIST 1.1. Responders were defined as patients 
with complete or partial responses by each criterion. Results: 
The median age of 83 men and 19 women was 64.3 years. 
The median alpha-fetoprotein and des-gamma-carboxy pro-
thrombin levels were 37.1 ng/mL and 1,780.0 mAU/mL, re-
spectively. The median maximal tumor size was 8.3 cm, and 
multiple tumors were observed in 36 patients (35.3%). Dur-
ing the follow-up period (median, 20.7 months), 21 patients 
(20.6%) died, with a mean survival time of 55.5 months. The 
cumulative survival rate was 96.1% at 6 months and 89.3% 
at 12 months. Responders, defined by the mRECIST at 1, 3, 
and 6 months after TARE, showed better survival outcomes 
than nonresponders (hazard ratio [HR]=5.736, p=0.008 at 
1 month; HR=3.145, p=0.022 at 3 months, and HR=2.887, 
p=0.061 at 6 months). The survival rates of responders and 
nonresponders defined by the RECIST 1.1 were similar (all 
p>0.05). Conclusions: Response evaluations that use the 
mRECIST provide more accurate prognoses than those that 
use the RECIST 1.1 in HCC patients treated with TARE. (Gut 
Liver 2020;14:765-774)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common 
malignancies and a common cause of cancer-related death.1 In 
2016, mortalities from HCC ranked second among cancer deaths 
in South Korea.2 Many patients are diagnosed at advanced stag-
es and are not candidates for curative treatment because of old 
age, co-morbid diseases, portal hypertension, liver dysfunction 
with cirrhosis, multiple tumors, portal vein invasion, or inability 
to secure a sufficient resection margin.3,4
Recently, the usefulness of transarterial radioembolization 
(TARE) for intrahepatic HCC has been reported.5-8 TARE is a 
liver-directed localized internal radiation therapy that uses an 
microembolic procedure for liver malignancies. It involves intra-
arterial injection of radioactive substances, such as yttrium-90 
(90Y)-loaded microspheres, to minimalize hepatic arterial flow 
alterations.5,9 TARE has showed a good safety profile, signifi-
cantly longer time to progression (TTP), better tumor control, 
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and higher quality of life. Thus, TARE can be an alternative 
treatment for patients with intermediate and advanced stages, 
who have a risk of procedure-related liver failure and complica-
tions after transarterial chemoembolization (TACE),5-8,10,11 and 
can be used to achieve a complete cure or as a bridging therapy 
for other curative options that reduce recurrence risk.12,13
Tumor responses have been commonly measured accord-
ing to the World Health Organization criteria and the Response 
Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) cri-
teria, which are based on tumor size and number.14,15 However, 
modified RECIST (mRECIST) criteria has recently been adopted 
for HCC, and this criteria considers the concepts of tumor viabil-
ity based on arterial enhancement and single linear summation, 
which ultimately simplify European Association for the Study 
of the Liver (EASL) criteria.15-19 Nowadays, mRECIST is widely 
used as a response evaluation method for several HCC therapies 
and provides good prognostic value for predicting overall sur-
vival (OS).20-23 However, the best response evaluation method 
for predicting treatment outcomes of HCC after TARE treatment 
remains controversial.6,24-27
In this study, we investigated the long-term outcomes ac-
cording to treatment response using RECIST 1.1 and mRECIST 
criteria, and compared the prognostic accuracy of both RECIST 




Between 2011 and 2017, HCC patients treated with TARE 
were recruited using a retrospective review of the patient data-
base at Yonsei Liver Center, Severance Hospital, Yonsei Univer-
sity College of Medicine.
The exclusion criteria were (1) age under 19 years; (2) Eastern 
Cooperative Oncology Group Performance Status >2; (3) extra-
hepatic HCC; (4) presence of ascites; (5) significant extrahepatic 
disease representing an imminent life-threatening outcome; (6) 
uncontrolled medical co-morbidities; (7) mortality of unknown 
cause that was not due to illness; (8) mortality that was abso-
lutely due to procedure-related complications; (9) follow-up 
loss or death within 3 months after TARE; (10) other treatment 
modalities such as TACE, intra-arterial chemotherapy, and sur-
gical resection within 6 months after TARE treatment, or large 
lipiodol uptake due to previous TACE that confounded response 
evaluation (Fig. 1).
The study protocol was in accordance with the 1975 Declara-
tion of Helsinki guidelines. The need for written informed con-
sent was waived because of the retrospective nature. The study 
procedure was approved by the institutional review board of 
Yonsei University Health System (IRB number: 4-2019-0035).
Fig. 1. Flowchart of the study population se-
lection.
HCC, hepatocellular carcinoma; TARE, tran-
sarterial radioembolization; ECOG, Eastern 
Cooperative Oncology Group; TACE, transar-
terial chemoembolization.
146 Patients with HCC who received TARE
between 2011 and 2017
127 atients with intrahepatic HCCP
102 atients were finally includedP







25 Patients were excluded due to
Mortality of unknown causes
Mortality absolutely due to procedure-related
complications
Follow-up loss or expired within 3 month
Other intra-arterial treatment or resection after TARE
Too large lipiodol uptake due to previous TACE
treatment that confounded the response evaluation
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2. HCC diagnosis
HCC was diagnosed histologically or clinically, according 
to the guidelines proposed by the Korea Liver Cancer Study 
Group.28,29 A positive finding for typical HCC on dynamic 
computed tomography or magnetic resonance imaging was 
described as an increased arterial enhancement followed by a 
decreased enhancement, compared to the liver (washout), in the 
portal or equilibrium phases.30
3. Treatment modality
Pretreatment angioscintigraphy with technetium-99 macro-
aggregated albumin scanning was performed in all patients, and 
the lung shunt fraction was assessed to avoid the extrahepatic 
spread of microspheres labeled with 90Y. Two to 3 weeks after 
pretreatment, TARE was performed with resin (SIR-Spheres®; 
Sirtex Medical, Sydney, Australia) or glass particles (Thera-
Sphere®; Biocompatibles UK Ltd., Surrey, UK) loaded with 90Y. 
The dose was determined from the planning angiogram and 
prepared in the nuclear medicine department, according to the 
preparation guide provide by the manufacturer. The target-
absorbed radiation doses to the normal liver and lungs should 
not exceed 70 Gy and 25 Gy, respectively. TARE was conducted 
according to previous guidelines.31
4. Assessment of the treatment responses using RECIST 1.1 
and mRECIST
The treatment responses were routinely assessed at 1, 3, and 5 
to 6 months after TACE sessions, using liver dynamic CT or MRI 
with a physical examination and blood tests. To minimize the 
possibility of false categorizations, two independent radiologists 
analyzed the images. In cases of disagreement, consensus of 
more than two radiologists reached.
The mRECIST and RECIST 1.1 guideline was applied for 
response evaluation.16,32 RECIST 1.1 defines target lesions as 
lesions which can be measured in at least one-dimension as 
above 1 cm with a spiral CT scan at baseline and be suitable 
for repeat measurement, and target lesions for mRECIST should 
show arterial enhancement additionally. Therefore, the target 
lesion was determined based on lesion size, as a largest single 
lesion.21 An infiltrative lesion that could be compared by mea-
surements before and after treatment was also regarded as a tar-
get lesion in this study. For a target lesion, the tumor response 
was defined by each criteria as a complete response (CR), partial 
response (PR), stable disease (SD) and progressive disease (PD). 
Like in literature, assessment of nontarget lesions included por-
tal vein thrombosis, which was suspected malignant due to the 
closed location to the tumor in either criteria, or viability with 
arterial enhancement in mRECIST. Finally, overall response was 
determined by combining the evaluation of target and nontar-
get lesions according to each criteria (Supplementary Table 1).
5. Definitions 
In addition to CR, PR, SD, and PR, “best response” was de-
fined as the most favorable response during 6 months after 
TARE treatment. “Responder” was defined as the sum of pa-
tients who showed either CR or PR, according to RECIST 1.1 
and mRECIST, which is similar to the definition of objective 
response that is used in the literature. “Nonresponder” was de-
fined as the sum of those who showed either SD or PD.
Table 1. Baseline Characteristics 
Variable Value (n=102)
Demographic variable
   Age, yr 64.3 (53.6–72.8)
   Male sex 83 (81.4)
   Body mass index, kg/m2 23.9 (21.3–25.8)
   Diabetes mellitus 44 (43.1)
   Hypertension 59 (57.8)
   Viral etiology 71 (69.6)
   Liver cirrhosis 28 (27.5)
Laboratory variables
   Platelet count, ×109/L 198.5 (121.3–261.5)
   Total bilirubin, mg/dL 0.6 (0.5–0.9)
   Serum albumin, g/dL 3.9 (3.5–4.1)
   Aspartate aminotransferase, IU/L 40.0 (28.8–64.3)
   Alanine aminotransferase, IU/L 28.5 (18.0–45.0)
   Alkaline phosphatase, IU/L 95.5 (76.0–138.5)
   Prothrombin time, INR 1.02 (0.96–1.10)
   AFP, ng/mL 37.1 (5.0–2,590.1)
      >200 39 (38.2)
      >400 36 (35.3)
   DCP, mAU/mL 1,780.0 (135.5–8,119.5)
      >13,000 19 (18.6)
Tumor characteristics
   Nodular/infiltrative 82 (80.4)/20 (19.6)
   Maximum tumor size, cm 8.3 (6.0–10.5)
   Multiple tumors 36 (35.3)
   Above 3 tumors 26 (25.5)
   Tumor burden >50% 10 (9.8)
   Bilobar distribution  28 (27.5)
   Portal vein thrombosis 19 (18.6)
      Segmentary order branch 5 (4.9)
      Second order branch 6 (5.9)
      First order branch 8 (7.8)
   Hepatic vein invasion 5 (4.9)
Data are presented as median (interquartile range) or number (%).
INR, international normalized ratio; AFP, alpha-fetoprotein; DCP, 
des-gamma-carboxyprothrombin.
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6. Statistical analysis
The Student t-tests and Mann-Whitney tests were used to 
compare quantitative variables. The chi-square tests and Fisher 
exact tests were used to compare qualitative variables. OS 
and progression-free survival (PFS) were calculated using the 
Kaplan-Meier analysis, and Cox proportional hazards model 
and a log-rank test that used Kaplan-Meier analysis were used 
to compare the hazard ratios between the results of the response 
evaluations at 1, 3, and 6 months after the initial TARE treat-
ment. The criteria with a higher chi-square value by the likeli-
hood ratio and linear trend tests were considered the better 
model for homogeneity and discriminatory ability. Furthermore, 
lower values for Akaike information criteria were considered 
better for discriminatory abilities. A p<0.05 was considered 
statistically significant, with a confidence interval of 95%. Sta-
tistical analyses were conducted using the IBM SPSS statistics 
software version 23.0 (IBM Corp., Armonk, NY, USA).
RESULTS
1. Patient characteristics
The workflow the study population selection is depicted in 
Fig. 1. In total, 146 patients were considered eligible for this 
study. After excluding 44 patients who met our exclusion cri-
teria, 102 patients who were treated with TARE for HCC were 
included in the analysis.
The baseline characteristics of the study population (83 men 
[81.4%] and 19 women [18.6%]) at the time of TARE treatment 
are shown in Table 1. The median patient age was 64.3 years. 
Seventy-one patients (69.6%) had viral hepatitis and 28 patients 
(27.5%) had liver cirrhosis. All patients had an Eastern Coopera-
tive Oncology Group Performance Status score of 0 or 1.
The median alpha-fetoprotein level was 37.1 ng/mL. In total, 
39 (38.2%) and 36 (35.3%) patients had alpha-fetoprotein levels 
>200 ng/mL and >400 ng/mL, respectively. The medial des-
gamma-carboxy prothrombin level was 1,708.0 mAU/mL. Nine-
teen patients (18.6%) had des-gamma-carboxy prothrombin 
levels >13,000 ng/mL.
The median diameter of the largest measurable lesion was 8.3 
cm. Thirty-six patients (35.3%) had multiple tumors, of whom 
26 (25.5%) had more than three tumors. Tumor invasion to pe-
ripheral branches of the portal vein was identified in 19 patients 
(18.6%). Hepatic vein invasion was identified in five patients 
(4.9%).
2. Survival outcomes after TARE
During the follow-up period (mean, 27.1 months; median, 
20.7 months), 21 patients (20.6%) died, with a mean survival of 
55.5 months (Supplementary Fig. 1). The cumulative survival 
rate was 96.1% at 6 months and 89.3% at 12 months.
3. Survival outcomes according to treatment response by 
RECIST 1.1 after TARE
The survival outcomes according to treatment response by 
RECIST 1.1 after TARE treatment are summarized in Supple-
mentary Table 2, and the corresponding Kaplan-Meier curves 
are described in Supplementary Fig. 2. The mean OS of two 
Table 2. Overall Survival Analysis of Responders and Nonresponders According to the RECIST 1.1 and mRECIST








RECIST 1.1 At 1 month Responders 2 Not reached 0.427 -
Nonresponders 99 55.0 (48.6–61.3) 21.072 (too wide) 0.598 
At 3 months Responders 13 64.9 (55.2–74.6) 0.130 -
Nonresponders 81 52.6 (45.4–59.8) 4.208 (0.557–31.779) 0.164 
At 6 months Responders 20 60.0 (50.1–70.0) 0.291 -
Nonresponders 51 54.6 (45.4–63.8) 2.013 (0.536–7.561) 0.300 
Best response Responders 23 60.9 (51.6–70.2) 0.115 -
Nonresponders 79 53.4 (45.9–61.0) 2.596 (0.759–8.881) 0.128 
mRECIST At 1 month Responders 31 61.4 (55.9–66.9) 0.008 -
Nonresponders 70 49.1 (40.8–57.5) 5.736 (0.133–24.676) 0.019 
At 3 months Responders 47 60.4 (52.5–68.2) 0.022 -
Nonresponders 47 48.4 (38.8–58.0) 3.145 (1.118–8.845) 0.030 
At 6 months Responders 42 60.2 (52.2–68.2) 0.061 -
Nonresponders 29 47.3 (35.0–59.6) 2.887 (0.907–9.187) 0.073 
Best response Responders 58 61.3 (54.7–67.9) 0.001 -
Nonresponders 44 44.7 (34.0–55.5) 4.594 (1.775–11.893) 0.002 
RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified RECIST; OS, overall survival; CI, confidence interval; HR, hazard ratio.
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patients (2.0%) who showed PR at 1 month was not calculated, 
whereas those of SD (n=96, 94.1%) and PD patients (n=3, 2.9%) 
were 56.6 and 9.1 months, respectively. At 3 months, PR (n=13, 
12.7%), SD (n=69, 67.6%), and PD patients (n=12, 11.8%) 
showed mean OS values of 64.9, 56.2, and 26.1 months, respec-
tively. At 6 months, PR (n=20, 19.6%), SD (n=39, 38.2%), and 
PD patients (n=12, 11.8%) showed mean OS values of 60.0, 62.7 
and 17.0 months, respectively. Regarding the best response, PR 
(n=23, 22.5%), SD (n=75, 73.5%), and PD patients (n=4, 3.9%) 
showed mean OS values of 60.9, 55.4, and 6.1 months, respec-
tively. No significant differences were noted in the mean OS 
values between PR and SD at 1, 3, and 6 months, and in best 
responses (all p>0.05), whereas PD patients consistently showed 
significantly lower mean OS values than the other patients (all 
p<0.05). Twenty-four patients (23.5%) experienced PD by RE-
CIST 1.1 during 6 months, and the cause of PD was intrahepatic 
and extrahepatic progression (n=24, 100%) (Supplementary 
Table 3).
4. Survival outcomes according to treatment response by 
mRECIST after TARE
Survival outcomes according to treatment response by mRE-
CIST 1.1 are summarized in Supplementary Table 2, and the 
corresponding Kaplan-Meier curves are described in Supple-
mentary Fig. 3. The mean OS of three patients (2.9%) who 
showed CR at 1 month after TARE was not calculated, whereas 
those of PR (n=28, 27.5%), SD (n=67, 65.7%), and PD patients 
(n=3, 2.9%) were 60.9, 51.3, and 9.1 months, respectively. At 3 
months, CR (n=12, 11.8%), PR (n=35, 34.3%), SD (n=33, 32.4%), 
and PD patients (n=14, 13.7%) showed mean OS values of 
56.3, 57.8, 55.7, and 25.0 months, respectively. CR patients at 
3 months showed significantly higher OS than those with SD 
(p=0.038); however, there was no significant difference in the 
mean OS between CR and PR (p=0.535) or between PR and SD 
(p=0.531). At 6 months, CR (n=10, 9.8%), PR (n=32, 31.4%), SD 
(n=12, 11.8%), and PD patients (n=17, 16.7%) showed mean OS 
values of 56.3, 58.3, 59.4, and 37.1 months, respectively, and 
there were no significant differences in CR, PR, and SD patients 
(CR vs PR, p=0.606; CR vs PR, p=0.894; PR vs SD, p=0.613). 
Regarding the best response, CR (n=14, 13.7%), PR (n=44.4, 
43.1%), SD (n=41, 40.2%), and PD patients (n=3, 2.9%) showed 
mean OS values of 57.5, 59.2, 48.0, and 9.1 months, respec-
tively. There were no significant differences in the mean OS val-
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RECIST 1.1 responders (n=2)
RECIST 1.1 nonresponders (n=99)
At 1 mo, log-rank p=0.427
RECIST 1.1 responders (n=13)
RECIST 1.1 nonresponders (n=81)
At 3 mo, log-rank p=0.130
RECIST 1.1 responders (n=20)
RECIST 1.1 nonresponders (n=51)
At 6 mo, log-rank p=0.291
RECIST 1.1 responders (n=23)
RECIST 1.1 nonresponders (n=79)
Best response, log-rank p=0.115
A B
C D
Fig. 2. Overall survival analysis of Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 responders and nonresponders using Kaplan-Meier 
analysis at 1 month (A), 3 months (B), and 6 months (C) and as the best response (D).
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showed significantly higher OS rates than SD patients (p=0.048 
and p=0.020, respectively). PD patients consistently showed 
significantly lower mean OS values than the other patients (all 
p<0.05). Thirty patients (29.4%) experienced PD by mRECIST 
during 6 months. The most common cause of PD by mRECIST 
at any time points (n=30) was intrahepatic and extrahepatic 
progression (n=28, 93.3%), and local control failure was infre-
quent in patients with PD (n=2, 6.6%) (Supplementary Table 3).
5. Better survival outcomes in responders
Survival outcomes of responders and nonresponders after 
TARE, according to RECIST 1.1 and mRECIST at each time 
point, are summarized in Table 2.
The mean OS values of the responders versus nonresponders 
according to RECIST 1.1 were statistically similar at 1 month 
(not reached vs 55.0 months, p=0.427), 3 months (64.9 months 
vs 52.6 months, p=0.130), and 6 months (60.0 months vs 54.6 
Table 3. Prognostic Accuracy of the mRECIST and RECIST 1.1 to Predict Mortality after Transarterial Radioembolization
Time point
Likelihood ratio (χ2) Linear trend (χ2) AIC
RECIST 1.1 mRECIST RECIST 1.1 mRECIST RECIST 1.1 mRECIST
At 1 months 0.943 (0.332) 6.574 (0.010) 0.530 (0.466) 5.530 (0.019) 109.916 104.707 
At 3 months 1.529 (0.216) 4.527 (0.033) 1.265 (0.261) 4.351 (0.037) 96.117 92.901 
At 6 months 0.073 (0.787) 1.797 (0.180) 0.071 (0.790) 1.802 (0.179) 68.051 66.270 
At best response 1.119 (0.290) 8.679 (0.003) 1.024 (0.312) 8.544 (0.003) 109.705 101.728 
The model with a higher chi-square value by the likelihood ratio test and the linear trend test was considered the better model for homogeneity 
and discriminatory ability. Furthermore, lower values for Akaike information criteria (AIC) were considered better for discriminatory ability. Likeli-
hood ratio and linear trend were shown as chi-square (p-value).
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mRECIST responders (n=31)
mRECIST nonresponders (n=70)
At 1 mo, log-rank p=0.008
mRECIST responders (n=47)
mRECIST nonresponders (n=47)
At 3 mo, log-rank p=0.022
mRECIST responders (n=42)
mRECIST nonresponders (n=29)
At 6 mo, log-rank p=0.061
mRECIST responders (n=58)
mRECIST nonresponders (n=44)
Best response, log-rank p=0.001
A B
C D
Fig. 3. Overall survival analysis of modified Response Evaluation Criteria in Solid Tumors (mRECIST) responders and nonresponders using Kaplan-
Meier analysis at 1 month (A), 3 months (B), and 6 months (C) and as the best response (D).
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months, p=0.291) after TARE. There was no significant differ-
ence in mean OS between responders and nonresponders ac-
cording to the best response by RECIST 1.1. (60.9 months vs 
53.4 months, p=0.115). Accordingly, no significantly different 
relative risk of deaths between responders and nonresponders 
was observed (all p>0.05) according to RECIST 1.1 (Table 2, Fig. 
2).
The mean OS of the responders was significantly higher or 
tended to be higher than that of nonresponders according to 
mRECIST (61.4 months vs 49.1 months at 1 month, p=0.008; 
60.4 months vs 48.4 months at 3 months, p=0.022; 60.2 months 
vs 47.3 months at 6 months, p=0.061; and 61.3 months vs 44.7 
months regarding the best response, p=0.001). The relative risk of 
death in nonresponders was significantly higher or tended to be 
higher than that of responders (unadjusted hazard ratio, 2.887 to 
5.736: p=0.019 at 1 month, p=0.030 at 3 months, p=0.073 at 6 
months, and p=0.002 with the best response) (Table 2, Fig. 2).
Regarding the best response, nonresponders according to 
mRECIST showed its association with OS in multivariate analy-
sis (adjusted hazard ratio, 3.432; p=0.015), with other variables 
such as tumor distribution, first branch portal vein thrombosis 
and hepatic vein invasion (Supplementary Tables 4, 5).
6. Prognostic performance of RECIST 1.1 and mRECIST re-
sponders
The prognostic performance of RECIST 1.1 and mRECIST to 
predict mortality was compared (Table 3). The likelihood ratios 
of RECIST 1.1 were not significant (0.943 at 1 month, 1.529 at 
3 months, 0.073 at 6 months, and 1.119 regarding the best re-
sponse; all p>0.05). In contrast, the likelihood ratios of mRECIST 
at 1 and 3 months were 6.574 (p=0.010) and 4.527 (p=0.033), 
respectively, with a best response of 1.797 (p=0.180). Regard-
ing the best response according to mRECIST, the likelihood 
ratio was 8.679 (p=0.003). Similarly, the linear trend of RECIST 
1.1 was not significant (0.530 at 1 month, 1.265 at 3 months, 
0.071 at 6 months, and 1.024 regarding the best response; all 
p>0.05). In contrast, the corresponding linear trend of mRECIST 
5.53 at 1 month (p=0.019), 4.527 at 6 months (p=0.037), and 
1.802 for best response, with borderline statistical significance 
(p=0.179). Regarding the best response according to mRECIST, 
the likelihood ratio and the linear trend were 8.679 and 8.544 (all 
p=0.003), respectively. The likelihood ratio and the linear trend 
tended to be higher in mRECIST than RECIST 1.1 at each time 
point. The Akaike information criteria values of mRECIST were 
lower than those of RECIST 1.1 (104.707 vs 109.916 at 1 month; 
92.901 vs 96.117 at 3 months; 66.270 vs 68.051 at 6 months; 
101.728 vs 109.705 regarding the best response).
7. PFS after TARE
PFS was longer in responders according to both criteria 
(p=0.043 in RECIST 1.1 and p=0.005 in mRECIST) (Supplemen-
tary Figs 4, 5). Regarding the best response before progression, 
nonresponders according to mRECIST showed its association 
with PFS in multivariate analysis (adjusted hazard ratio, 2.151; 
p=0.014), while those according to RECIST 1.1 did not (Supple-
mentary Tables 6-9).
DISCUSSION
TARE reduces tumor size and arterial enhancement on dy-
namic imaging, which indicate tumor shrinkage and necrosis, 
in a manner similar to TACE.27 Furthermore, TARE has been 
shown to be a safe and efficacious treatment strategy com-
pared with conventional TACE, with a decreased risk of adverse 
events, an enhanced response rate, and a prolonged TTP.6,7,11 To 
decide whether we should further inspect patients for a delayed 
response to TARE or switch to another treatment modality is of 
paramount importance. To prevent disease progression, we must 
be able to discriminate the confounding responses that are due 
to the specific treatment mechanism of TARE (e.g., posttreat-
ment inflammation, transient increase in lesion size associated 
with successful necrosis, peritumoral changes, and hemorrhage 
in the necrotic tumor) from true responses that indicate tumor 
reduction.26,27
In the present study, at early time points (1 or 3 months), the 
proportions of responders using RECIST 1.1 were significantly 
lower than using mRECIST. This indicates a clear methodologi-
cal difference between the size-based RECIST 1.1 and enhance-
ment-based mRECIST criteria. PD, as assessed by RECIST 1.1 
and mRECIST, was significantly associated with poor survival at 
all-time points after TARE (all p<0.05). Furthermore, there were 
no significant difference in OS between responders and nonre-
sponders by RECIST 1.1, and responders, as defined by mRECIST 
at 1 and 3 months, showed significantly better survival than 
nonresponders (all p<0.05). In addition, prognosis stratification 
by mRECIST showed significantly higher chi-square values and 
lower Akaike information criteria values than by RECIST 1.1 at 
all-time points, which suggests the superior prognostic accuracy 
of mRECIST over RECIST 1.1.
Our study has several clinical implications. First, our results 
directly show that mRECIST criteria are superior to RECIST 1.1 
for evaluating patient prognosis after TARE, despite the useful-
ness of enhancement criteria such as EASL and mRECIST after 
TARE has been controversial. Salem et al.6 evaluated long-term 
outcomes after TARE for HCC and noted that objective respond-
ers by EASL criteria showed better median OS predictions. Fur-
thermore, Weng et al.24 noted that based on the responders at 
3 months after TARE, by Choi criteria, the tumor density was a 
superior to predictor of TTP and OS. In this study, the respond-
ers at 3 months by mRECIST criteria also showed significance 
for TTP and OS (p=0.004 and p=0.077). Recently, Riaz et al.25 
performed 3-, 6-, and 12-month landmark analyses of 202 pa-
tients with solitary HCC and showed that the objective respond-
ers by EASL associated with longer survivals compared to size-
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based criteria. Our results also suggest that enhancement-based 
response evaluation criteria, such as mRECIST and EASL, might 
provide more detailed and accurate prognoses after TARE for 
HCC treatment.
Second, our landmark analyses also suggest that response 
evaluations at delayed time points after TARE should be consid-
ered. Indeed, the proportion of patients who achieved CR (n=3 
[2.9%] at 1 month; n=12 [11.8%] at 3 months) and PR (n=28 
[27.5%] at 1 month; n=35 [34.3%] at 3 months) by mRECIST 
increased over time. In agreement with our findings, Vouche et 
al.33 showed that the proportion of patients who achieved CR 
based on enhancement criteria increased over time, which indi-
cates the clinical significance of response evaluations at delayed 
time points after TARE. In cases of external radiation, Kim et 
al.34 showed that response evaluations based on enhancement 
criteria showed better predictions of pathologic response, and 
their findings were obtained from surgical specimens after 
radiotherapy plus concurrent hepatic arterial infusion che-
motherapy. In this study, the correlation of the enhancement-
based response with the degree of pathological tumor response 
gradually increased, until 6 months after radiation. All of these 
findings suggest that the clinical decision to maintain or switch 
treatment modality can be delayed until 3 to 6 months after the 
radiation-based treatment was performed for HCC.
Third, in our study, PD was a strong predictor of poor sur-
vival by both criteria at all-time points. The augmented arte-
rial enhancement that is observed in the peritumoral area after 
TARE can sometimes be an important confounding factor.26,27 
However, if new intrahepatic or extrahepatic arterial enhanced 
lesions outside of the primary lesion are observed, which indi-
cate local control failure, it is not difficult to confirm PD. The 
failure of HCC local control with stage migration has been one 
of the most important predictors of poor survival,35 in support 
of our findings. Recently, Khor et al.36 reported that the major-
ity PD patterns after TARE revealed the development of new 
intrahepatic lesions predominantly in Asian patients with HCC. 
Similarly, most patients with PD by mRECIST (n=28, 93.3%) had 
intrahepatic or extrahepatic progression, rather than primary 
lesion progression. All of these findings suggest that PD after 
TARE, especially PD with new lesions outside of the primary 
tumor lesion, should be regarded as insufficient responses to 
TARE and a prerequisite for additional or alternative treatments, 
even at the early time points.
Despite the strengths of our study, several issues remain 
unresolved. First, due to the retrospective nature of the study, 
patients might not be representative of real-world situations. 
Due to the low probability of adverse events after treatment 
with TARE, a significant proportion of patients preferred TARE 
than surgical resection or other intra-arterial therapies, and this 
high-selection might have biased the survival of our study par-
ticipants: indeed, the survival rates of our study seems longer 
(mean, 55.5 months) than those of other studies of TARE (about 
36 months of mean OS and about 10 to 17 months of median 
OS) that have been reported in literature.6,7,10,11 Furthermore, 
other bi-dimensional enhancement criteria were not evaluated: 
however, in several previous studies, simplified one-dimensional 
assessments that use mRECIST have been shown to be sufficient 
prognosticators in patients treated with TACE.22,37 Finally, the 
association between radiological and pathological treatment 
responses could not be assessed. Further studies that recruit 
patients who received surgical resection after TARE can resolve 
this issue.
In conclusion, the response evaluations that used mRECIST 
were more prognostic than those that used RECIST 1.1 in pa-
tients with HCC who were treated with TARE. Clinical decisions 
to wait for the maximal response to TARE or to add or switch to 
another therapeutic modality might be delayed until 3 months 
after TARE, based on mRECIST criteria.
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